{
  "id": "dna-damage-response",
  "title": "DNA Damage Response",
  "lang": "en",
  "source_lang": "en",
  "summary": "The DNA damage response detects genome injury and coordinates repair, cell-cycle control, and cell fate to preserve genetic stability.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "DDR",
    "DNA damage signaling network",
    "DNA damage surveillance response"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/dna-damage-response/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/dna-damage-response/",
      "json": "https://aiwiki.page/zh/dna-damage-response.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "The DNA damage response (DDR) is the interconnected network of molecular processes through which cells detect damage to DNA, signal its presence, and coordinate protective responses. These responses include DNA repair, temporary interruption of the cell cycle, changes in gene expression and metabolism, and, in some circumstances, permanent proliferative arrest or programmed cell death. DNA repair is therefore one component of the DDR rather than a synonym for the entire system.\n\nThe response preserves the integrity of the genome despite continuous exposure to chemical instability, replication errors, metabolic by-products, and environmental agents. Its importance is evident in inherited disorders of damage surveillance and repair, many of which involve developmental abnormalities, neurological impairment, immune deficiency, or predisposition to cancer. Conversely, the dependence of some tumors on particular DDR pathways creates opportunities for selective treatment.\n\nMost detailed molecular descriptions concern mammalian cells, but the underlying problem is universal. Bacteria, archaea, and eukaryotes all possess systems that connect DNA damage recognition to repair and cellular physiology. These systems differ in their components and organization; they should not be understood as a single invariant pathway shared by every organism."
    },
    {
      "heading": "Sources of damage and the problem of recognition",
      "text": "DNA damage is a chemical or structural alteration of DNA that interferes with its normal use or preservation. It is distinct from a mutation, which is a change in sequence that has become established. An oxidized base, for example, is a lesion; if copying across that lesion introduces an incorrect base pair that subsequently becomes fixed, the result is a mutation. Conversely, repair can remove damage without any permanent sequence change. This distinction explains why the DDR limits both immediate cellular injury and the longer-term accumulation of inherited changes.\n\nEndogenous damage arises through several mechanisms. Spontaneous hydrolysis can remove bases from the sugar–phosphate backbone or deaminate cytosine to uracil. Reactive oxygen species can oxidize bases and sugars, while reactive aldehydes generated by normal metabolism can produce DNA adducts and crosslinks. Topoisomerases normally cut and reseal DNA to manage torsional stress; interruption of their catalytic cycles can leave protein-linked breaks. Damage also arises when DNA-copying machinery encounters difficult sequences, insufficient nucleotide supplies, or obstacles associated with transcription.\n\nEnvironmental agents produce characteristic, though not exclusively agent-specific, lesions. Ultraviolet radiation generates cyclobutane pyrimidine dimers and related photoproducts. Ionizing radiation can produce base damage, single-strand breaks, double-strand breaks, and clustered combinations of lesions. Tobacco smoke contains chemicals whose activated metabolites form bulky DNA adducts. Certain anticancer drugs deliberately create crosslinks, trap topoisomerase–DNA intermediates, or disrupt DNA synthesis. The biological effect depends not only on the initial chemical alteration but also on its location, abundance, persistence, and interaction with replication.\n\nA central difficulty is recognizing abnormal DNA within a vast excess of normal DNA. Different sensors therefore detect different features rather than a universal “damage” signal. Some recognize altered bases or distorted helices; others recognize exposed DNA ends, single-stranded DNA, or a polymerase that has stopped progressing. The same initial lesion may consequently activate different pathways in different contexts. A nick that is relatively straightforward to seal outside S phase can become a broken replication fork when encountered during DNA replication.\n\nDamage burden cannot be reduced to a single reliable number of “DNA injuries per cell per day.” Estimates depend on which lesion classes are counted, the tissue, metabolic state, analytical method, and repair rate. A measured abundance is also not the same as a formation rate: rapidly repaired lesions may be generated frequently yet remain scarce at any one time. DDR biology therefore distinguishes the production of damage, its steady-state abundance, and the cellular consequences of lesions that persist."
    },
    {
      "heading": "Sensors, signaling kinases, and chromatin organization",
      "text": "In mammalian cells, three related protein kinases occupy central positions in damage signaling: ATM, ATR, and DNA-PKcs. These large enzymes belong to the phosphatidylinositol 3-kinase-related kinase family, although their principal DDR substrates are proteins rather than membrane lipids. Their functions overlap but are not interchangeable. ATM is strongly associated with responses to DNA double-strand breaks, ATR with replication-associated single-stranded DNA, and DNA-PKcs with the repair of DNA ends by classical non-homologous end joining.\n\nThe MRE11–RAD50–NBS1 complex, commonly called MRN, recognizes and processes DNA ends and helps recruit and activate ATM. ATM then phosphorylates numerous substrates involved in repair, checkpoint control, and chromatin regulation. One prominent substrate is the histone variant H2AX. Phosphorylation of H2AX at serine 139 produces γH2AX, which can extend across large chromatin regions surrounding a break. The mediator MDC1 binds this modification and helps assemble further signaling machinery. Thus, a local discontinuity in DNA can generate a much larger molecular platform.\n\nATR is recruited through its partner ATRIP to single-stranded DNA coated with replication protein A, or RPA. Such structures form when DNA unwinding becomes uncoupled from synthesis, or when DNA ends undergo resection. Efficient ATR activation also depends on appropriate DNA structures and regulatory proteins, including TOPBP1 or ETAA1 in distinct settings. The RAD9–RAD1–HUS1 clamp and its loader help connect particular DNA junctions to the TOPBP1-dependent pathway. ATR activation therefore reflects both exposed single-stranded DNA and the organization of neighboring replication or repair structures.\n\nProtein modification creates specificity and amplification. Phosphorylation changes protein activity or binding, while ubiquitination and SUMOylation regulate recruitment, retention, and turnover. The ubiquitin ligases RNF8 and RNF168 help establish damage-associated chromatin marks that support assembly of factors such as 53BP1 and BRCA1-containing complexes. These events occur within chromatin, where DNA is wrapped around histone proteins and organized into nucleosomes. Chromatin remodeling and histone modification influence whether repair proteins can reach a lesion and which repair pathway becomes available.\n\nThis organization is often described as a sequence of sensors, mediators, transducers, and effectors, but the categories are functional conveniences. MRN both senses damage and participates in its processing; repair changes the DNA structures that activate signaling; and signaling alters subsequent processing. DNA-PK, formed when the Ku70–Ku80 complex recruits DNA-PKcs to DNA ends, similarly couples recognition with repair execution. The DDR is therefore a feedback-controlled network rather than a simple one-way cascade."
    },
    {
      "heading": "Checkpoints and control of cell-cycle progression",
      "text": "DNA damage checkpoints delay cell-cycle transitions when damaged DNA would otherwise be copied or segregated. They do not inspect every nucleotide before allowing progression. Instead, they respond to molecular signals generated by damage and replication problems, adjusting the activity of cyclin-dependent kinases and other regulators. Their protective value is temporal: they provide additional opportunity for repair, reduce inappropriate initiation of DNA synthesis, and prevent premature entry into mitosis. A checkpoint defect can allow proliferation despite damage even when the enzymes that directly repair DNA remain functional.\n\nThe G1 response is closely associated with the p53 tumor suppressor. Damage signaling stabilizes and activates p53 partly by altering its interactions with negative regulators such as MDM2. As a transcription factor, p53 increases expression of genes including CDKN1A, which encodes p21. p21 inhibits cyclin-dependent kinases, supporting retention of the retinoblastoma protein in a growth-suppressive state and restricting activation of E2F-dependent genes needed for S phase. This response is especially important when cells encounter damage before initiating genome duplication.\n\nDuring S phase and at the G2–M transition, CHK1 and CHK2 relay major checkpoint signals. ATR preferentially activates CHK1, whereas ATM is a principal activator of CHK2, although extensive cross-talk occurs. These kinases regulate CDC25 phosphatases, which normally remove inhibitory phosphates from cyclin-dependent kinases. Together with WEE1-mediated inhibitory phosphorylation, suppression of CDC25 activity restrains CDK1 and delays mitotic entry. In S phase, ATR–CHK1 signaling also limits inappropriate origin firing and helps maintain an adequate supply of replication resources.\n\nCheckpoint activity is graded and dynamic rather than a binary switch. Different lesions, doses, and cell types generate distinct signaling patterns. p53 can show repeated pulses after some forms of damage, while other conditions produce more sustained activity. The eventual output depends on the signaling history, the cell’s proliferative state, available survival signals, and the expression of downstream effectors. The same initiating lesion can therefore lead to a transient delay in one cell and permanent arrest or death in another.\n\nRecovery requires active reversal of signaling after lesions are repaired or replication resumes. Phosphatases, protein degradation, and restoration of cyclin-dependent kinase activity help terminate the arrest. Importantly, resumption of division does not by itself prove that all damage has been removed. Cells may tolerate residual lesions or bypass checkpoint enforcement. Defects in checkpoint maintenance can permit chromosome segregation with incompletely replicated DNA, producing anaphase bridges, chromosome breakage, or micronuclei. Checkpoint status and repair completion must therefore be measured separately."
    },
    {
      "heading": "Repair pathway coordination and the choice of mechanism",
      "text": "The DDR coordinates multiple repair pathways because different lesions require different chemical solutions. Base excision repair removes many small, non-helix-distorting lesions through lesion-specific DNA glycosylases, processing of the resulting abasic site, repair synthesis, and ligation. Nucleotide excision repair removes short DNA segments containing bulky distortions, including ultraviolet photoproducts. DNA mismatch repair corrects many replication-associated base mismatches and insertion–deletion loops. These pathways have their own recognition systems, but their intermediates and failures can activate broader checkpoint signaling.\n\nDouble-strand breaks pose a special problem because the continuity of both DNA strands has been lost. Classical non-homologous end joining brings DNA ends together through Ku, DNA-PKcs, and associated factors, with final sealing by a complex containing DNA ligase IV and XRCC4. Processing may be needed when ends are chemically damaged or incompatible. End joining can restore the original sequence when suitable ends are directly rejoined, but processing can also produce small insertions or deletions. It is therefore inaccurate to treat every end-joining event as necessarily mutagenic.\n\nHomologous recombination uses a related DNA sequence as a template. In dividing somatic cells, the sister chromatid is usually the preferred template, making this pathway particularly relevant in S and G2. Resection of break ends generates single-stranded DNA that is initially coated by RPA. BRCA2 promotes assembly of RAD51 filaments, which search for homology and initiate strand invasion. Repair synthesis and resolution of the resulting intermediates can restore missing information, but recombination must be controlled to avoid inappropriate exchanges or rearrangements.\n\nPathway choice depends heavily on whether DNA ends undergo resection. CDK-regulated factors, including CtIP, promote resection in appropriate cell-cycle stages. BRCA1-associated activities generally support resection and homologous recombination, whereas 53BP1 and its downstream effectors can protect ends and favor end joining in particular chromatin contexts. Alternative end-joining pathways, including polymerase θ-mediated end joining, use short regions of sequence similarity and can produce characteristic deletions. These are competing and partially redundant routes, not independent repair systems acting without coordination.\n\nInterstrand crosslinks illustrate why pathway integration is essential. A crosslink covalently joins opposite DNA strands, preventing their normal separation. The Fanconi anemia pathway coordinates recognition and processing of many replication-associated crosslinks. Monoubiquitination of the FANCD2–FANCI complex is a central regulatory event, and subsequent repair can require nucleases, translesion synthesis, and homologous recombination. The precise sequence depends on lesion chemistry and the way replication encounters it. A repair intermediate generated by one pathway can become the substrate for another, while defective coordination may convert a repairable lesion into a chromosome break."
    },
    {
      "heading": "Replication stress and protection of replication forks",
      "text": "Replication stress refers to impaired progression or completion of DNA replication. It can result from DNA lesions, shortages or imbalances of nucleotides, difficult-to-replicate sequences, excessive origin firing, or collisions between replication and transcription. RNA–DNA hybrids called R-loops can contribute in some settings by leaving a displaced single DNA strand and obstructing replication. Oncogene activation frequently increases replication stress by disrupting the coordination between growth, nucleotide production, transcription, and DNA synthesis.\n\nA stalled fork is not automatically a broken fork. When a replicative polymerase slows while the helicase continues unwinding, single-stranded DNA accumulates and becomes coated with RPA. This activates ATR signaling and recruits protective factors. ATR–CHK1 signaling helps restrain additional origin firing, preserve replication proteins, and prevent widespread fork failure. If excessive single-stranded DNA exhausts the available RPA pool, protection can fail across many genomic regions, contributing to a state often termed replication catastrophe.\n\nFork remodeling can stabilize replication intermediates or create opportunities for repair. In fork reversal, the newly synthesized strands pair with one another while the parental strands reanneal, producing a four-way junction. Proteins including SMARCAL1, ZRANB3, and HLTF can promote remodeling in appropriate contexts. Reversal can protect a fork from an immediate obstacle, but the regressed arm must itself be protected against inappropriate nuclease degradation. BRCA1, BRCA2, RAD51, and other proteins contribute to fork protection, although their roles are not identical to their functions in double-strand-break repair.\n\nCells can also tolerate a lesion without immediately removing it. Specialized translesion DNA polymerases synthesize across damaged templates that block replicative polymerases. Their accuracy depends on the polymerase and lesion: bypass is not uniformly error-prone. Polymerase η, for example, can copy accurately across common ultraviolet-induced cyclobutane thymine dimers, and its loss causes xeroderma pigmentosum variant. Other tolerance mechanisms include repriming DNA synthesis downstream of a lesion, which leaves a gap to be filled later, and template switching using newly synthesized undamaged DNA.\n\nPersistent replication problems can survive into later cell-cycle stages. Common fragile sites are genomic regions that show increased breakage under particular replication-stress conditions, often because replication is difficult to complete there. Some incompletely replicated regions undergo mitotic DNA synthesis, while unresolved intermediates can form ultrafine bridges during chromosome segregation. In daughter cells, 53BP1 nuclear bodies can mark inherited replication-associated lesions. These observations show that genome maintenance is not confined to a single checkpoint: damage can be transmitted between phases and generations, requiring successive layers of surveillance."
    },
    {
      "heading": "Cell fate, tissue responses, and immune signaling",
      "text": "Successful repair commonly leads to checkpoint release and renewed proliferation. When damage persists, however, DDR signaling can redirect cell fate. The result depends on damage severity and duration, cell identity, developmental stage, and the balance between pro-survival and pro-death pathways. Highly proliferative cells, terminally differentiated cells, and stem cells do not necessarily respond in the same way. A lesion burden that triggers apoptosis in one tissue may cause prolonged arrest or altered function in another.\n\nApoptosis removes damaged cells through an organized program rather than allowing uncontrolled disintegration. p53 can increase expression of pro-apoptotic genes such as PUMA and NOXA. These influence the BCL-2 protein family and can promote mitochondrial outer-membrane permeabilization, release of cytochrome c, and activation of caspases. This is one route by which damage signaling connects nuclear genome surveillance to the mitochondrion. Apoptosis is not always p53-dependent, and p53 activation does not inevitably result in death.\n\nCellular senescence is a durable state of proliferative arrest accompanied by broader changes in cellular organization and function. Persistent DDR signaling, including that arising from dysfunctional telomeres, can help establish or maintain senescence. The p53–p21 and p16–retinoblastoma pathways are important but variably engaged. Many senescent cells produce a senescence-associated secretory phenotype containing inflammatory mediators, growth factors, and proteases. Its composition depends on cell type and the inducing stimulus. Senescence can suppress the expansion of damaged cells while also changing the surrounding tissue environment.\n\nDNA damage can stimulate innate immune pathways when DNA appears outside its usual compartment. Chromosome fragments or missegregated chromosomes can form micronuclei whose envelopes are prone to rupture. Exposed DNA can then become accessible to cyclic GMP–AMP synthase, cGAS. This enzyme produces the second messenger cGAMP, which activates STING and downstream signaling that can induce type I interferons and other inflammatory programs. The connection is context-dependent: chromatin organization, compartmentalization, and pathway expression influence whether a given DNA structure activates the response.\n\nDDR-associated inflammation can have different consequences at different times. It can contribute to immune recognition and tissue repair, but persistent signaling can also sustain chronic inflammatory states. In tumors, these pathways may interact with both antitumor immunity and mechanisms that support tumor persistence. Similarly, associations among accumulated DNA damage, senescence, and aging do not establish a single universal mechanism of aging. Tissue regeneration, stem-cell maintenance, immune clearance, and systemic physiology all influence the outcome of damage at the organismal level."
    },
    {
      "heading": "Inherited disorders and genome instability in cancer",
      "text": "Inherited DDR disorders reveal the consequences of disrupting particular molecular functions. Ataxia-telangiectasia, caused by pathogenic variants affecting ATM, is associated with progressive neurological impairment, immune abnormalities, radiation sensitivity, and increased cancer susceptibility. Nijmegen breakage syndrome involves NBN, which encodes the NBS1 component of MRN, and commonly includes microcephaly, growth impairment, immunodeficiency, and cancer predisposition. Although these disorders affect related signaling machinery, their clinical features are not identical, illustrating the specialized developmental and tissue functions of individual DDR proteins.\n\nDefects in lesion-specific repair produce different patterns. Xeroderma pigmentosum usually results from impaired nucleotide excision repair and is characterized by marked sensitivity to ultraviolet damage and greatly increased skin-cancer risk. The variant form instead involves POLH, encoding polymerase η. Cockayne syndrome involves defective responses to transcription-blocking damage and has prominent developmental and neurological manifestations without the same skin-cancer pattern. Fanconi anemia is associated with defective interstrand-crosslink repair, congenital abnormalities in some affected individuals, bone-marrow failure, and predisposition to particular cancers.\n\nDNA repair also intersects with adaptive immune development. V(D)J recombination deliberately generates double-strand breaks to assemble antigen-receptor genes, and classical end joining is required to reconnect the DNA. Defects in components such as Artemis or DNA ligase IV can therefore impair lymphocyte development and cause immunodeficiency. Other programmed antibody-gene changes, including class-switch recombination, likewise require tightly regulated handling of DNA breaks. Genome protection is not simply the avoidance of all breakage: it includes the safe management of breaks that are biologically necessary.\n\nCancer often develops through selection for cells that can continue proliferating despite genomic abnormalities. Loss of p53 function can weaken checkpoint and cell-fate responses, while defects in homologous recombination or mismatch repair can increase particular classes of mutation. Constitutional pathogenic variants in BRCA1 or BRCA2 increase susceptibility to several cancers through disruption of genome maintenance. Lynch syndrome results from inherited predisposition associated with mismatch-repair genes or mechanisms that silence one of them. Neither condition means that every cell is continuously unable to repair all kinds of DNA damage.\n\nThe relation between DDR activity and cancer is consequently dual. Before transformation, functional surveillance suppresses the survival and propagation of dangerous genome changes. After a tumor has developed, its remaining repair and checkpoint pathways may be essential for tolerating oncogene-driven replication stress and treatment-induced damage. Tumor genomes can contain mutational signatures that reflect past exposures or repair defects, but a historical signature does not always demonstrate a current functional deficiency. Restoration of repair during tumor evolution can leave the earlier genomic pattern intact."
    },
    {
      "heading": "Therapeutic targeting and biomarkers",
      "text": "Radiotherapy and many cytotoxic drugs exploit DNA damage or its consequences. Ionizing radiation generates several lesion classes, with double-strand breaks and clustered damage contributing substantially to cell killing. Platinum compounds form DNA adducts and crosslinks, while topoisomerase inhibitors stabilize normally transient enzyme–DNA intermediates. Antimetabolites can disrupt nucleotide metabolism or DNA synthesis. Their effects depend not only on the lesions they produce but also on proliferation, drug delivery, damage recognition, repair capacity, and the ability of cells to execute arrest or death.\n\nA major principle of targeted DDR treatment is synthetic lethality: disruption of either of two functions alone can be tolerated, whereas their combined loss is lethal. In 2005, studies demonstrated strong sensitivity of BRCA-deficient cells to inhibition of poly(ADP-ribose) polymerase, particularly PARP1. PARP inhibitors subsequently became an established treatment class for defined cancer settings. Their action includes inhibition of PARylation and, to varying degrees, trapping PARP proteins on DNA, which can obstruct replication. The interaction with BRCA deficiency is more complex than the simple accumulation of unrepaired single-strand breaks.\n\nClinical use of a DDR-targeted drug depends on the cancer type, disease setting, specific agent, and relevant molecular findings. Pathogenic variants in BRCA1 or BRCA2 are important biomarkers in several settings, while broader measures of homologous-recombination deficiency may also be used. Such measures are not interchangeable. A DNA sequence variant, a genomic scar, an expression pattern, and a functional assay each capture a different aspect of repair biology. Alterations in different repair genes also do not necessarily confer equal sensitivity to the same drug.\n\nResistance can arise through multiple mechanisms. Secondary changes can restore a functional reading frame in BRCA genes, allowing renewed homologous recombination. Altered end protection or resection can partially restore recombination in some genetic backgrounds. Other mechanisms include changes in PARP1, increased drug efflux, and restoration of replication-fork protection. Consequently, a tumor that was initially sensitive can evolve under treatment without losing the genomic evidence of its original repair defect. This distinction is important when interpreting persistent biomarkers after resistance emerges.\n\nATR, CHK1, WEE1, DNA-PK, and polymerase θ are additional therapeutic targets under investigation. The aim is often to exploit a tumor’s dependence on a remaining checkpoint or repair route, or to enhance the effects of another treatment. Selectivity is constrained because normal proliferating tissues also require genome maintenance. Bone marrow and the gastrointestinal epithelium are among the tissues that can be affected by damage-inducing regimens. Rational combinations therefore require evidence about both antitumor activity and overlapping toxicity; a molecular interaction observed in cultured cells does not by itself establish clinical benefit."
    },
    {
      "heading": "Discovery, experimental methods, and unresolved questions",
      "text": "The DDR concept emerged from the convergence of DNA repair genetics, radiation biology, cell-cycle research, and studies of human disease. In bacteria, the SOS response established a model in which DNA damage changes gene expression: activated RecA promotes self-cleavage of the LexA repressor, derepressing genes involved in repair, damage tolerance, and cell-division control. This bacterial system is not the equivalent of the mammalian ATM–ATR network, but it demonstrated that damage could induce a coordinated physiological program rather than merely engage constitutive repair enzymes.\n\nIn eukaryotes, yeast genetics was especially influential. The 1989 work of Ted Weinert and Leland Hartwell on RAD9 helped establish the idea of a DNA damage checkpoint: a surveillance function that delays cell-cycle progression rather than directly performing repair. Identification of the ATM gene in 1995 connected a major human radiosensitivity syndrome to a central signaling kinase. The discovery that H2AX is rapidly phosphorylated around double-strand breaks in 1998 provided a widely used way to visualize damage-associated chromatin. The 2015 Nobel Prize in Chemistry recognized Tomas Lindahl, Paul Modrich, and Aziz Sancar for mechanistic studies of DNA repair, an essential foundation of the broader DDR field.\n\nModern experiments combine complementary measurements. γH2AX and 53BP1 foci reveal damage-associated protein assemblies, while flow cytometry measures DNA content, replication, and cell-cycle distribution. Comet assays measure DNA migration from individual cells under conditions sensitive to particular classes of breaks or alkali-labile sites. DNA-fiber assays track the lengths and organization of newly synthesized DNA tracts to investigate fork progression and origin use. Reporter systems estimate repair outcomes at defined breaks, and genome editing enables systematic tests of gene function.\n\nNo single assay measures the complete response. γH2AX is a signaling marker, not a direct count of double-strand breaks under every condition, and extensive phosphorylation can accompany apoptosis or replication stress. Repair reporters simplify genomic context and can be influenced by changes in cell-cycle composition. Laser microirradiation produces lesion mixtures that depend on wavelength and experimental conditions. Even apparent fork slowing can reflect altered labeling, nucleotide metabolism, or population selection. Reliable interpretation therefore depends on orthogonal assays, appropriate time courses, and controls that distinguish damage production from defective repair.\n\nOpen questions concern how cells integrate lesion identity, chromatin state, replication timing, and tissue-specific physiology into a coherent outcome. Researchers are investigating how damage-associated assemblies are organized in space, how repair is coordinated with transcription and three-dimensional genome structure, and how DNA-derived signals reach inflammatory pathways. A major clinical challenge is to measure current repair capacity rather than infer it solely from inherited variants or historical genomic scars. Single-cell approaches, functional biomarkers, organoid models, and spatial analyses are being used to examine heterogeneity that can be obscured in bulk measurements."
    }
  ],
  "links": [
    "dna",
    "dna-repair",
    "cell-cycle",
    "gene-expression",
    "apoptosis",
    "genome",
    "cancer",
    "bacteria",
    "archaea",
    "eukaryote",
    "mutation",
    "hydrolysis",
    "metabolism",
    "transcription-biology",
    "dna-replication",
    "enzyme",
    "chromatin",
    "histone",
    "nucleosome",
    "mitosis",
    "transcription-factor",
    "dna-mismatch-repair",
    "non-homologous-end-joining",
    "homologous-recombination",
    "mitochondrion",
    "telomere",
    "innate-immunity",
    "vdj-recombination",
    "class-switch-recombination",
    "nobel-prize-in-chemistry",
    "flow-cytometry",
    "genome-editing"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}